Revisiting Timing and Decision Modeling for Allogeneic Hematopoietic Stem-Cell Transplantation in Myelodysplastic Syndromes

C Cutler - Journal of Clinical Oncology, 2024 - ascopubs.org
The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …

Targeted therapies for myelodysplastic Syndromes/Neoplasms (MDS): current landscape and future directions

A Bidikian, JP Bewersdorf, RM Shallis… - Expert Review of …, 2024 - Taylor & Francis
Introduction Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of
hematologic malignancies that are stratified into high-risk (HR-MDS) and low-risk (LR-MDS) …

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms

WH Lee, CC Lin, CH Tsai, FM Tien, MY Lo… - Blood Cancer …, 2024 - nature.com
In 2022, two novel classification systems for myelodysplastic syndromes/neoplasms (MDS)
have been proposed: the International Consensus Classification (ICC) and the 2022 World …

Allogeneic Hematopoietic Cell Transplantation in Elderly Patients with Myelodysplastic Syndromes: Considerations and Challenges

E Schulz, SZ Pavletic, A Mina - Seminars in Hematology, 2024 - Elsevier
Myelodysplastic syndromes/neoplasms (MDS) and related diseases are highly
heterogeneous myeloid stem cell cancers that predominantly affect the elderly. The only …

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee

F Onida, N Gagelmann, Y Chalandon, G Kobbe… - Blood, 2024 - ashpublications.org
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with
either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell …

Association between gene mutations and certain blood cell indices in patients diagnosed with myelodysplastic neoplasms

QH Nguyen, MP Vu, TA Tran… - World Academy of …, 2024 - spandidos-publications.com
Gene mutations play a crucial role in the pathogenesis of myelodysplastic neoplasms
(MDS). The present study aimed to assess the association between some gene mutations …

Myeloid Neoplasms

G Deeb, S Li - Precision Pathology of Cancer: From Basic …, 2024 - books.google.com
Myeloid neoplasms consist of a heterogeneous group of hematopoietic disorders derived
from bone marrow progenitor cells. The signs and symptoms of patients with myeloid …

Clinical characteristics and prognostic analysis of gene mutations in Myelodysplastic Syndrome

L Ding, Y Lai, Y Chen, SA Andoh, M Zou, Z Long… - 2024 - researchsquare.com
Myelodysplastic syndromes (MDS) are heterogeneous clonal diseases characterized by
cytopenia caused by ineffective hematopoiesis and high risk of transformation into acute …

Гетерогенність гемопоетичних клітин-попередників у культурі клітин in vitro та in vivo у нормі та при мієлодиспластичному синдромі: дисертація на здобуття …

М Пахаренко - 2023 - ekmair.ukma.edu.ua
Дисертація на здобуття наукового ступеня доктора філософії в галузі знань 09"
Біологія" за спеціальністю 091" Біологія". Національний університет" Києво …

[引用][C] Causes of death in patients with myelodysplastic syndrome and spliceosome mutations

PD Kontoyiannis, AS Peddireddy, K Sasaki, K Chien… - Leukemia Research, 2024 - Elsevier